More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries to maintain its dominance in the GLP-1 market.
Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill.
It is ... [2074 chars]